Univest
Univest
  • Markets

3 Technical Fibres Maker, Generic Drugs Maker and Auto Components Maker Stocks With a Strong Future Roadmap: Garware Technical Fibres, Glenmark Pharmaceuticals and UNO Minda

  • November 18, 2026
  • Posted by: Kunal Singla
  • Category: Best Stocks
No Comments
3 Technical Fibres Maker, Generic Drugs Maker and Auto Components Maker Stocks With a Strong Future Roadmap: Garware Technical Fibres, Glenmark Pharmaceuticals and UNO Minda

Garware Technical Fibres, Glenmark Pharmaceuticals and UNO Minda: ROE of 14.7% to 28.1% and FY22 to FY26 revenue CAGR of 7.0% to 23.8%. Prices as of 17 Nov 2026.

Quick Answer

The three fishing net, generic drug and auto part stocks to watch are Garware Technical Fibres, Glenmark Pharmaceuticals and UNO Minda. Their return on equity ranges from 14.7% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.0% to 23.8%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while UNO Minda has the fastest revenue growth at 23.8% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.

Fishing net, generic drug and auto part stocks bring together companies with a visible plan for the years ahead. Garware Technical Fibres, Glenmark Pharmaceuticals and UNO Minda cover a technical fibres maker, a generic drugs maker and an auto components maker.

This list covers three fishing net, generic drug and auto part stocks with complete current figures: Garware Technical Fibres, Glenmark Pharmaceuticals and UNO Minda. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Fishing Net, Generic Drug and Auto Part Stocks?
  • Fishing Net, Generic Drug and Auto Part Stocks at a Glance
  • Why Do Fishing Net, Generic Drug and Auto Part Stocks Have a Strong Roadmap in India?
  • Why Garware Technical Fibres Features Among These Fishing Net, Generic Drug and Auto Part Stocks
  • Why Glenmark Pharmaceuticals Features Among These Fishing Net, Generic Drug and Auto Part Stocks
  • Why UNO Minda Features Among These Fishing Net, Generic Drug and Auto Part Stocks
  • Garware Technical Fibres vs Glenmark Pharmaceuticals vs UNO Minda on Key Financials
  • Key Risks to Check Before Investing in Fishing Net, Generic Drug and Auto Part Stocks
  • Final Thoughts on Fishing Net, Generic Drug and Auto Part Stocks
    • What are fishing net, generic drug and auto part stocks?
    • Which fishing net, generic drug and auto part stocks are covered in this list?
    • Why do fishing net, generic drug and auto part stocks have a strong future roadmap in India?
    • How has Garware Technical Fibres performed financially?
    • How has Glenmark Pharmaceuticals performed financially?
    • How has UNO Minda performed financially?
    • What risks should investors check before buying fishing net, generic drug and auto part stocks?
    • Is this list of fishing net, generic drug and auto part stocks investment advice?

What Are Fishing Net, Generic Drug and Auto Part Stocks?

Fishing net, generic drug and auto part stocks are listed companies that make fishing nets, ropes and technical textiles, make generic and branded medicines for India and global markets, and make switches, lighting and sensors for vehicles. Their earnings depend on fibre demand, medicine demand and vehicle output.

Fishing Net, Generic Drug and Auto Part Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Garware Technical Fibres 728.9 7,140 34.0 30.1 14.7 0.03
Glenmark Pharmaceuticals 2,615.8 60,103 33.4 35.7 28.1 0.06
UNO Minda 1,388.1 61,685 47.8 36.1 17.5 0.40

On valuation, Glenmark Pharmaceuticals trades at a P/E below the industry P/E, while Garware Technical Fibres and UNO Minda trade above it, which reflects the growth the market already expects. Readers comparing fishing net, generic drug and auto part stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in fishing net, generic drug and auto part stocks can use the coming numbers to test whether growth is holding.

Why Do Fishing Net, Generic Drug and Auto Part Stocks Have a Strong Roadmap in India?

Fishing net, generic drug and auto part stocks have a strong roadmap in India because rising demand for strong technical fibres, steady demand for medicines and rising vehicle output keep widening the market for these companies.

  • Technical fibres. Fishing and sport use strong nets and ropes.
  • Generic drugs. Patients need affordable treatment.
  • Auto components. New vehicles carry more electronics.

Why Garware Technical Fibres Features Among These Fishing Net, Generic Drug and Auto Part Stocks

Among the fishing net, generic drug and auto part stocks on this list, Garware Technical Fibres is a Pune-based maker of technical textiles such as fishing nets, aquaculture cages, sports nets, ropes and agricultural nets. It sells in India and across global markets.

The company has a return on equity of 14.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 7,140 crore. The stock trades at a P/E of 34.0, above the industry P/E of 30.1.

Revenue rose from Rs 1,215 crore in FY22 to Rs 1,594 crore in FY26, a compound annual growth rate of 7.0%. Net profit for FY26 was Rs 198 crore, a net margin of 12.5%. In the June 2026 quarter, revenue grew 29.3% year on year to Rs 491 crore, while net profit rose 21.5% to Rs 64.5 crore.

Roadmap: The company is widening its range in aquaculture, sports and agri applications, where demand for engineered nets is rising. Long relationships with overseas buyers help it add new products steadily.

What to watch: Follow aquaculture and sports netting demand and the pace of new product launches.

Why Glenmark Pharmaceuticals Features Among These Fishing Net, Generic Drug and Auto Part Stocks

Among the technical fibre, pharma maker and vehicle switch shares on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.

Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%.

In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.

Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.

Why UNO Minda Features Among These Fishing Net, Generic Drug and Auto Part Stocks

Among the three companies on this list, UNO Minda is a Gurugram-based global automotive supplier of switches, lighting, sensors, alloy wheels, controllers and acoustic products for two-wheelers, passenger vehicles and commercial vehicles.

In the June 2026 quarter, revenue grew 23.6% year on year to Rs 5,563 crore, while net profit rose 2.1% to Rs 316 crore. Revenue rose from Rs 8,376 crore in FY22 to Rs 19,692 crore in FY26, a compound annual growth rate of 23.8%.

Net profit grew from Rs 347 crore in FY22 to Rs 1,284 crore in FY26, which works out to a compound annual growth rate of 38.6%. The company has a return on equity of 17.5%, a debt to equity ratio of 0.40 and a market capitalisation of Rs 61,685 crore. The stock trades at a P/E of 47.8, above the industry P/E of 36.1.

Roadmap: The company is growing in electronics, electric vehicle components and premium products, which carry higher value per vehicle. Acquisitions and joint ventures have widened its technology base.

What to watch: Track electric vehicle component orders, new product launches and international growth.

Garware Technical Fibres vs Glenmark Pharmaceuticals vs UNO Minda on Key Financials

The table below sets the three fishing net, generic drug and auto part stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Garware Technical Fibres 1,215 1,594 7.0% 198 12.5%
Glenmark Pharmaceuticals 12,472 17,443 8.7% 1,362 7.8%
UNO Minda 8,376 19,692 23.8% 1,284 6.5%

Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. UNO Minda combines the largest FY26 revenue at Rs 19,692 crore with the fastest revenue growth, a 23.8% compound annual rate. A useful habit with fishing net, generic drug and auto part stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Company Q1 FY26 Revenue (Rs Cr) Q1 FY27 Revenue (Rs Cr) Year-on-Year Growth
Garware Technical Fibres 380 491 29.3%
Glenmark Pharmaceuticals 3,291 4,084 24.1%
UNO Minda 4,501 5,563 23.6%

Key Risks to Check Before Investing in Fishing Net, Generic Drug and Auto Part Stocks

Every theme carries risks that deserve a check before any decision. For these fishing net, generic drug and auto part stocks, the main points are: Long-term technical fibre, pharma maker and vehicle switch shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Demand cycles. Sales can vary with seasons and rates.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Raw material costs. Ingredient and packaging prices can move margins.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter fishing net, generic drug and auto part stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Fishing Net, Generic Drug and Auto Part Stocks

Fishing net, generic drug and auto part stocks suit investors who prefer to study business strength before price moves. Garware Technical Fibres, Glenmark Pharmaceuticals and UNO Minda each have a clear plan to grow. Based on the 17 November 2026 close, Garware Technical Fibres trades at Rs 728.9, Glenmark Pharmaceuticals at Rs 2,615.8 and UNO Minda at Rs 1,388.1. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these fishing net, generic drug and auto part stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track fishing net, generic drug and auto part stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are fishing net, generic drug and auto part stocks?

Ans. Fishing net, generic drug and auto part stocks are listed companies that make fishing nets, ropes and technical textiles, make generic and branded medicines for India and global markets, and make switches, lighting and sensors for vehicles. Their earnings depend on fibre demand, medicine demand and vehicle output. This list looks at three of them, Garware Technical Fibres, Glenmark Pharmaceuticals and UNO Minda, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.

Which fishing net, generic drug and auto part stocks are covered in this list?

Ans. This list covers Garware Technical Fibres, Glenmark Pharmaceuticals and UNO Minda. Based on the 17 November 2026 close, Garware Technical Fibres traded at Rs 728.9, Glenmark Pharmaceuticals at Rs 2,615.8 and UNO Minda at Rs 1,388.1. Their return on equity ranges from 14.7% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.0% to 23.8%.

Why do fishing net, generic drug and auto part stocks have a strong future roadmap in India?

Ans. Fishing net, generic drug and auto part stocks have a strong roadmap in India because rising demand for strong technical fibres, steady demand for medicines and rising vehicle output keep widening the market for these companies. The main drivers are as follows. Technical fibres. Fishing and sport use strong nets and ropes. Generic drugs. Patients need affordable treatment. Auto components. New vehicles carry more electronics. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Garware Technical Fibres performed financially?

Ans. Revenue rose from Rs 1,215 crore in FY22 to Rs 1,594 crore in FY26, a compound annual growth rate of 7.0%. Net profit for FY26 was Rs 198 crore, a net margin of 12.5%. In the June 2026 quarter, revenue grew 29.3% year on year to Rs 491 crore, while net profit rose 21.5% to Rs 64.5 crore. The company has a return on equity of 14.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 7,140 crore. The stock trades at a P/E of 34.0, above the industry P/E of 30.1. Looking ahead, the company is widening its range in aquaculture, sports and agri applications, where demand for engineered nets is rising. Long relationships with overseas buyers help it add new products steadily.

How has Glenmark Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

How has UNO Minda performed financially?

Ans. Revenue rose from Rs 8,376 crore in FY22 to Rs 19,692 crore in FY26, a compound annual growth rate of 23.8%. Net profit grew from Rs 347 crore in FY22 to Rs 1,284 crore in FY26, which works out to a compound annual growth rate of 38.6%. In the June 2026 quarter, revenue grew 23.6% year on year to Rs 5,563 crore, while net profit rose 2.1% to Rs 316 crore. The company has a return on equity of 17.5%, a debt to equity ratio of 0.40 and a market capitalisation of Rs 61,685 crore. The stock trades at a P/E of 47.8, above the industry P/E of 36.1. Looking ahead, the company is growing in electronics, electric vehicle components and premium products, which carry higher value per vehicle. Acquisitions and joint ventures have widened its technology base.

What risks should investors check before buying fishing net, generic drug and auto part stocks?

Ans. Investors should check a few risks before buying fishing net, generic drug and auto part stocks. Demand cycles. Sales can vary with seasons and rates. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of fishing net, generic drug and auto part stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



Best Stocks fishing net formulations and automotive components stocks Garware Technical Fibres generic drug and auto part stocks Glenmark Pharmaceuticals pharma maker and vehicle switch shares synthetic ropes technical fibre Uno Minda
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply